Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.

L SamsS KrugerV HeinemannD BarariaS HaebeS AligM HaasD ZhangC B WestphalenS OrmannsP MetzgerJ WernerO WeigertM von Bergwelt-BaildonF RatajS KoboldStefan Boeck

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2021)

Chemotherapy with FOLFIRNOX or gemcitabine/nab-paclitaxel induces variable changes in circulating T-cell populations that may provide prognostic information in PDAC.

Keyphrases

regulatory t cells
locally advanced
rectal cancer
squamous cell carcinoma
advanced non small cell lung cancer
dendritic cells
radiation therapy
chemotherapy induced
health information
immune response
healthcare
social media